EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer

Sytse C. van Beek, Noor van Ginkel, Joost L. Boormans, André N. Vis

Uro-Technology Journal · 2024

DOI: 10.31491/utj.2024.09.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Uro-Technology Journal, 2024. Verfasst von Sytse C. van Beek und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Beek, S. C. V., Ginkel, N. V., Boormans, J. L., & Vis, A. N. (2024). Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer. Uro-Technology Journal. https://doi.org/10.31491/utj.2024.09.025

Vancouver

Beek SCV, Ginkel NV, Boormans JL, Vis AN. Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer. Uro-Technology Journal. 2024. doi:10.31491/utj.2024.09.025

BibTeX
@article{Beek2024,
  author = {Beek, Sytse C. van and Ginkel, Noor van and Boormans, Joost L. and Vis, André N.},
  title = {Neoadjuvant chemotherapy should only be considered in patients with cT3-T4a muscle-invasive bladder cancer},
  journal = {Uro-Technology Journal},
  year = {2024},
  doi = {10.31491/utj.2024.09.025}
}
Kostenlos starten →